Last updated on June 2019

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma


Brief description of study

This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Clinical Study Identifier: NCT03448978

Find a site near you

Start Over

Virgina Cancer Specialists

Fairfax, VA United States
4.83miles
  Connect »

The Center for Cancer and Blood Disorders

Bethesda, MD United States
7.35miles
  Connect »